News coverage about uniQure N.V. (NASDAQ:QURE) has trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. uniQure N.V. earned a news impact score of 0.01 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.0571279843676 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

uniQure N.V. (NASDAQ QURE) opened at 7.94 on Friday. uniQure N.V. has a 12 month low of $4.72 and a 12 month high of $9.15. The company’s 50 day moving average price is $7.91 and its 200 day moving average price is $6.27. The firm’s market capitalization is $202.95 million.

uniQure N.V. (NASDAQ:QURE) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.05. The company had revenue of $4.94 million during the quarter, compared to analysts’ expectations of $2.92 million. uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%. Analysts anticipate that uniQure N.V. will post ($3.07) EPS for the current year.

A number of equities research analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $17.00 price target on shares of uniQure N.V. and gave the company a “buy” rating in a research report on Tuesday, May 16th. ValuEngine downgraded shares of uniQure N.V. from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded shares of uniQure N.V. from a “buy” rating to a “hold” rating in a research report on Thursday. Cowen and Company reiterated a “buy” rating on shares of uniQure N.V. in a research report on Wednesday, May 24th. Finally, Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the company a “buy” rating in a research report on Sunday, July 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $14.88.

COPYRIGHT VIOLATION WARNING: “uniQure N.V. (QURE) Given Coverage Optimism Rating of 0.01” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at

In other news, insider Harald Petry sold 58,075 shares of uniQure N.V. stock in a transaction that occurred on Monday, June 26th. The stock was sold at an average price of $6.01, for a total value of $349,030.75. Following the completion of the transaction, the insider now owns 155 shares in the company, valued at approximately $931.55. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last quarter, insiders sold 173,460 shares of company stock valued at $1,042,986. Company insiders own 0.73% of the company’s stock.

About uniQure N.V.

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Insider Buying and Selling by Quarter for uniQure N.V. (NASDAQ:QURE)

Receive News & Stock Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related stocks with our FREE daily email newsletter.